Genprex (NASDAQ:GNPX – Get Free Report)’s share price traded down 6% during trading on Monday . The company traded as low as $6.72 and last traded at $7.21. Approximately 27,461 shares changed hands during mid-day trading, a decline of 10% from the average daily volume of 30,610 shares. The stock had previously closed at $7.67.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on GNPX shares. Wall Street Zen raised Genprex from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a research report on Friday. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.
Check Out Our Latest Analysis on Genprex
Genprex Trading Up 3.9%
Genprex (NASDAQ:GNPX – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($14.08) EPS for the quarter.
Institutional Investors Weigh In On Genprex
A number of institutional investors and hedge funds have recently bought and sold shares of GNPX. Susquehanna International Group LLP boosted its holdings in Genprex by 11.7% during the 3rd quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock worth $58,000 after acquiring an additional 35,661 shares during the last quarter. Mayflower Financial Advisors LLC purchased a new stake in shares of Genprex in the first quarter valued at about $36,000. Finally, Manchester Financial Inc. purchased a new stake in shares of Genprex in the first quarter valued at about $36,000. 14.05% of the stock is owned by hedge funds and other institutional investors.
About Genprex
Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.
In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.
See Also
- Five stocks we like better than Genprex
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.
